Antibodies – Talk Bio

Novartis Pays $30M Upfront to Leqembi Creator BioArctic for Access to Blood-Brain Barrier Technology

2 days ago talkbio0Tagged Antibodies, BioArctic, Blood - brain barrier anatomy, BrainTransporter platform, Leqembi, milestone payments, Nerve Degeneration, Novartis, Partnership, royalties

Novartis; BioArctic; BrainTransporter platform; blood-brain barrier; neurodegeneration; Leqembi; partnership; antibody; milestone payments; royalties

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

4 weeks ago talkbio0Tagged Antibodies, Biopharma, Clinical Trials, Dosage Forms, Japan, Kissei, Partnership, Thyroid associated opthalmopathies, Veligrotug, Viridian, VRDN-003

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal

Alphabet’s Calico Strikes $596M Deal for Mabwell’s Anti-Aging Antibody

2 months ago talkbio0Tagged aging-related diseases, Alphabet, Antibodies, Biopharma, Calico, interleukin-11, Licensing, Mabwell

Calico; Alphabet; Mabwell; anti-aging; biotech; IL-11 antibody; 9MW3811; exclusive licensing; aging-related diseases; biopharma deal

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

4 months ago4 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

German cancer antibody biotech eyes SPAC as route to Nasdaq

4 months ago talkbio0Tagged Antibodies, German language, Nasdaq, SPAC, Veraxa

Veraxa, Antibodies, SPAC, German language, Nasdaq

AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer

4 months ago talkbio0Tagged Antibodies, Antibody-Drug Conjugates, AstraZeneca, Daiichi, deruxtecan-nxki, Enhertu, fam-trastuzumab, first-line therapy, HER2-positive metastatic breast cancer, pertuzumab, Progression-Free Survival, Sankyo

Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab

Isomorphic Labs Secures $600M to Accelerate AI-Powered Drug Discovery

5 months ago talkbio0Tagged Antibodies, Aortic Valve Insufficiency, Demis, expansion, Hassabis, Isomorphous, Laboratory test finding, U.S.

AI drug discovery, Isomorphic Labs, Demis Hassabis, funding round, antibodies, US expansion

Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

7 months ago talkbio0Tagged Antibodies, Beyfortus, blockbuster sales, Growth, Infant, Market, Protection, Respiratory syncytial virus, sanofi, U.S.

Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus

Leap Therapeutics’ Stock Plummets Following Disappointing DKK1 Antibody Results in Gastric Cancer Trials

7 months ago talkbio0Tagged Antibodies, Clinical Trials, DKK1 gene, LEAP, Malignant neoplasm of stomach, Performance

Leap Therapeutics, DKK1 Antibody, Gastric Cancer, Clinical Trials, Stock Performance

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

8 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.